Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/19648510/ below:

Risk of human papillomavirus-associated cancers among persons with AIDS

Affiliations

• ¹ Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072, Rockville, MD 20852, USA. chaturva@mail.nih.gov

• PMID: 19648510
• PMCID: PMC2728745
• DOI: 10.1093/jnci/djp205

Item in Clipboard

Anil K Chaturvedi et al. J Natl Cancer Inst. 2009.

• ¹ Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072, Rockville, MD 20852, USA. chaturva@mail.nih.gov

• PMID: 19648510
• PMCID: PMC2728745
• DOI: 10.1093/jnci/djp205

Item in Clipboard

Background: Although risk of human papillomavirus (HPV)-associated cancers of the anus, cervix, oropharynx, penis, vagina, and vulva is increased among persons with AIDS, the etiologic role of immunosuppression is unclear and incidence trends for these cancers over time, particularly after the introduction of highly active antiretroviral therapy in 1996, are not well described.

Methods: Data on 499 230 individuals diagnosed with AIDS from January 1, 1980, through December 31, 2004, were linked with cancer registries in 15 US regions. Risk of in situ and invasive HPV-associated cancers, compared with that in the general population, was measured by use of standardized incidence ratios (SIRs) and 95% confidence intervals (CIs). We evaluated the relationship of immunosuppression with incidence during the period of 4-60 months after AIDS onset by use of CD4 T-cell counts measured at AIDS onset. Incidence during the 4-60 months after AIDS onset was compared across three periods (1980-1989, 1990-1995, and 1996-2004). All statistical tests were two-sided.

Results: Among persons with AIDS, we observed statistically significantly elevated risk of all HPV-associated in situ (SIRs ranged from 8.9, 95% CI = 8.0 to 9.9, for cervical cancer to 68.6, 95% CI = 59.7 to 78.4, for anal cancer among men) and invasive (SIRs ranged from 1.6, 95% CI = 1.2 to 2.1, for oropharyngeal cancer to 34.6, 95% CI = 30.8 to 38.8, for anal cancer among men) cancers. During 1996-2004, low CD4 T-cell count was associated with statistically significantly increased risk of invasive anal cancer among men (relative risk [RR] per decline of 100 CD4 T cells per cubic millimeter = 1.34, 95% CI = 1.08 to 1.66, P = .006) and non-statistically significantly increased risk of in situ vagina or vulva cancer (RR = 1.52, 95% CI = 0.99 to 2.35, P = .055) and of invasive cervical cancer (RR = 1.32, 95% CI = 0.96 to 1.80, P = .077). Among men, incidence (per 100 000 person-years) of in situ and invasive anal cancer was statistically significantly higher during 1996-2004 than during 1990-1995 (61% increase for in situ cancers, 18.3 cases vs 29.5 cases, respectively; RR = 1.71, 95% CI = 1.24 to 2.35, P < .001; and 104% increase for invasive cancers, 20.7 cases vs 42.3 cases, respectively; RR = 2.03, 95% CI = 1.54 to 2.68, P < .001). Incidence of other cancers was stable over time.

Conclusions: Risk of HPV-associated cancers was elevated among persons with AIDS and increased with increasing immunosuppression. The increasing incidence for anal cancer during 1996-2004 indicates that prolonged survival may be associated with increased risk of certain HPV-associated cancers.

PubMed Disclaimer

Risk of in situ human…

Risk of in situ human papillomavirus (HPV)–associated cancers among persons with AIDS, according…

Risk of in situ human papillomavirus (HPV)–associated cancers among persons with AIDS, according to time relative to AIDS onset. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for in situ HPV-associated cancers are presented across the following five risk periods relative to AIDS onset: a = 60–25 months before AIDS; b = 24–7 months before AIDS; c = 6 months before to 3 months after AIDS (the AIDS onset period); d = 4–27 months after AIDS; and e = 28–60 months after AIDS. The AIDS onset period was excluded from trend analyses. P_trend values were calculated by use of Poisson regression. All statistical tests were two-sided.

Risk of invasive human papillomavirus…

Risk of invasive human papillomavirus (HPV)–associated cancers among persons with AIDS, according to…

Risk of invasive human papillomavirus (HPV)–associated cancers among persons with AIDS, according to time relative to AIDS onset. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for invasive HPV-associated cancers are presented across the following five risk periods relative to AIDS onset: a = 60–25 months before AIDS; b = 24–7 months before AIDS; c = 6 months before to 3 months after AIDS (the AIDS onset period); d = 4–27 months after AIDS; and e = 28–60 months after AIDS. The AIDS onset period was excluded from trend analyses. P_trend values were calculated by use of Poisson regression. All statistical tests were two-sided.

Incidence of in situ and…

Incidence of in situ and invasive human papillomavirus (HPV)–associated cancers in the 4-…

Incidence of in situ and invasive human papillomavirus (HPV)–associated cancers in the 4- to 60-month period after AIDS, according to CD4 T-cell count at AIDS onset. Incidence of HPV-associated cancers per 100 000 person-years is shown according to the following five CD4 T-cell count categories: a = 0–99 cells per cubic millimeter; b = 100–199 cells per cubic millimeter; c = 200–299 cells per cubic millimeter; d = 300–399 cells per cubic millimeter; and e = 400–499 cells per cubic millimeter. Analyses were restricted to persons diagnosed with AIDS during the era of highly active antiretroviral therapy (1996–2004). A) Anal cancer among men. B) Anal cancer among women. C) Cervical cancer. D) Oropharyngeal cancer. E) Cancer of the penis. F) Cancer of the vagina or vulva. Broken lines = in situ cancers; solid lines = invasive cancers. The number of cancer patients in each CD4 T-cell count category is also shown. Error bars = 95% confidence intervals.

• Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.

  Frisch M, Biggar RJ, Goedert JJ. Frisch M, et al. J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10. doi: 10.1093/jnci/92.18.1500. J Natl Cancer Inst. 2000. PMID: 10995805

• StatBite: Proportion of specific cancers caused by HPV.

  [No authors listed] [No authors listed] J Natl Cancer Inst. 2010 Jun 16;102(12):839. doi: 10.1093/jnci/djq224. Epub 2010 Jun 8. J Natl Cancer Inst. 2010. PMID: 20530763 No abstract available.

• Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.

  Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK. Jemal A, et al. J Natl Cancer Inst. 2013 Feb 6;105(3):175-201. doi: 10.1093/jnci/djs491. Epub 2013 Jan 7. J Natl Cancer Inst. 2013. PMID: 23297039 Free PMC article.

• Global burden of human papillomavirus and related diseases.

  Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Forman D, et al. Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Vaccine. 2012. PMID: 23199955 Review.

• Comprehensive control of human papillomavirus infections and related diseases.

  Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Bosch FX, et al. Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Vaccine. 2013. PMID: 24331745 Review.

• Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.

  Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH. Coppock JD, et al. Neoplasia. 2013 Jun;15(6):620-30. doi: 10.1593/neo.13432. Neoplasia. 2013. PMID: 23730210 Free PMC article.

• Combination antiretroviral therapy and cancer risk.

  Borges ÁH. Borges ÁH. Curr Opin HIV AIDS. 2017 Jan;12(1):12-19. doi: 10.1097/COH.0000000000000334. Curr Opin HIV AIDS. 2017. PMID: 27755153 Free PMC article. Review.

• Sexually transmitted diseases treatment guidelines, 2015.

  Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Workowski KA, et al. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. MMWR Recomm Rep. 2015. PMID: 26042815 Free PMC article.

• Performance and acceptability of self-collected human papillomavirus testing among women living with HIV.

  Wang R, Lee K, Gaydos CA, Anderson J, Keller J, Coleman J. Wang R, et al. Int J Infect Dis. 2020 Oct;99:452-457. doi: 10.1016/j.ijid.2020.07.047. Epub 2020 Jul 30. Int J Infect Dis. 2020. PMID: 32738484 Free PMC article. Clinical Trial.

• Management of Head and Neck Cancers With or Without Comorbid HIV Infection in Botswana.

  McGinnis GJ, Ning MS, Bvochora-Nsingo M, Chiyapo S, Balang D, Ralefala T, Lin A, Zetola NM, Grover S. McGinnis GJ, et al. Laryngoscope. 2021 May;131(5):E1558-E1566. doi: 10.1002/lary.29206. Epub 2020 Oct 24. Laryngoscope. 2021. PMID: 33098322 Free PMC article.

1. 1. Parkin DM. Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(suppl 3):S11–S25. - PubMed
2. 1. Gillison ML, Shah KV. Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr. 2003;(31):57–65. - PubMed
3. 1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. - PubMed
4. 1. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500–1510. - PubMed
5. 1. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–432. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3